

Memo

To: CP-CTNet Colleagues

From: CP-CTNet Steering Committee

Date: October 25, 2024

Subject: Quarterly Steering Committee Information Dissemination

1. NCI Update

- Dr. Szabo said the grant renewal submissions are due next week.

2. CP-CTNet update

- Dr. Seema Khan (NWU) was appointed as the new CP-CTNet Steering Committee chair and her role will begin at the January 17, 2025 meeting.
- Drs. Julie Bauman (UAZ) and Patty Thompson (UAZ) will Co-Chair I-SCORE 2025.
- The CP-CTNet Cross-network Data & Safety Monitoring Board (DSMB) convened on September 13, 2024.

3. DMACC Update

- ePRO (Medidata eCOA)
 - The DMACC and DCP collectively decided to further investigate possible solutions in the next grant cycle.
- Report Requests
 - The DMACC continues to work on several newly requested reports/updates to existing reports: participant status table and count, adverse events, cumulative inclusion enrollment, automated AQuIP supplemental reports and daily and weekly enrollment reports.
- Clinical Trials Methodology and Biostatistics
 - Dr. Kim presented statistical monitoring of CP-CTNet clinical trials and EDI Survey analyses.
- I-SCORE 2025
 - The first planning meeting with DCP will occur in November 2024. The meeting is scheduled for March 27 and 28, 2025.

4. CP-CTNet Committee Updates

- **EDI Committee Update**
 - The EDI subcommittee for Education scheduled a webinar for **November 20, 2024 – Just Ask! Increasing Diversity in Cancer Clinical Research Training Programs**. Dr. Nadine Barrett, of Wake Forest University, is the guest speaker.

5. Cross-Network Trial Updates

- **INT21-05-01 Tri-Ad5 and N-803 Vaccines for Lynch Syndrome**
 - Dr. Szabo reported that accrual is excellent and the study was presented to the CP-CTNet Cross-network DSMB with no concerns.
 - Dr. Leslie Ford added that the success of this cross-network study is validation for the network.
- **The INT22-09-01 Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer**
 - Dr. Lisa Barroilhet reported that enrollment should begin in the next two months.
- **INT23-14-01 Refining Tamoxifen Dose for Premenopausal Breast Cancer Prevention (RENAISSANCE): A Phase II Single Arm Trial**
 - Dr. Brandy Heckman-Stoddard reported that this study is activated at three of the eleven sites and that NWU has already accrued six participants.

6. New Topics

- N/A

7. Concept Solicitation Cycles #21-25

Cycle #	Steering Committee Date	Concept Solicitation Date	Concept Due Date
21	Oct. 25, 2024	Nov. 1, 2024	Jan. 10, 2025
22	Jan. 17, 2025	Jan. 24, 2025	Apr. 5, 2025
23	Mar. 27, 2025	Apr. 4, 2025	Jun. 6, 2025
24	Jul. 18, 2025	Jul. 25, 2025	Sep. 26, 2025

25	Oct. 24, 2025	Oct. 31, 2025	Jan. 9, 2026
----	---------------	---------------	--------------

8. Next Steering Committee Meeting

- **Date: January 17, 2025**